Literature DB >> 27342080

IV Spanish Consensus Conference on Helicobacter pylori infection treatment.

Javier P Gisbert1, Javier Molina-Infante2, Javier Amador3, Fernando Bermejo4, Luis Bujanda5, Xavier Calvet6, Manuel Castro-Fernández7, Antonio Cuadrado-Lavín8, J Ignasi Elizalde9, Emili Gene10, Fernando Gomollón11, Ángel Lanas11, Carlos Martín de Argila12, Fermín Mearin13, Miguel Montoro14, Ángeles Pérez-Aisa15, Emilio Pérez-Trallero16, Adrián G McNicholl17.   

Abstract

Helicobacter pylori approximately infect 50% of Spanish population and causes chronic gastritis, peptic ulcer and gastric cancer. Until now, three consensus meetings on H.pylori infection had been performed in Spain (the last in 2012). The changes in the treatment schemes, and the increasing available evidence, have justified organizing the IVSpanish Consensus Conference (March 2016), focused on the treatment of this infection. Nineteen experts participated, who performed a systematic review of the scientific evidence and developed a series of recommendation that were subjected to an anonymous Delphi process of iterative voting. Scientific evidence and the strength of the recommendation were classified using GRADE guidelines. As starting point, this consensus increased the minimum acceptable efficacy of recommended treatments that should reach, or preferably surpass, the 90% cure rate when prescribed empirically. Therefore, only quadruple therapies (with or without bismuth), and generally lasting 14 days, are recommended both for first and second line treatments. Non-bismuth quadruple concomitant regimen, including a proton pump inhibitor, clarithromycin, amoxicillin and metronidazole, is recommended as first line. In the present consensus, other first line alternatives and rescue treatments are also reviewed and recommended. Copyright Â
© 2016 Elsevier España, S.L.U., AEEH y AEG. All rights reserved.

Entities:  

Keywords:  Bismuth; Bismuto; Clarithromycin; Claritromicina; Helicobacter pylori; Inhibidor de la bomba de protones; Metronidazol; Metronidazole; Omeprazol; Omeprazole; Proton pump inhibitor

Mesh:

Substances:

Year:  2016        PMID: 27342080     DOI: 10.1016/j.gastrohep.2016.05.003

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  20 in total

Review 1.  Dealing with uncertainty in the treatment of Helicobacter pylori.

Authors:  Xavier Calvet
Journal:  Ther Adv Chronic Dis       Date:  2018-02-12       Impact factor: 5.091

Review 2.  Best Practice Recommendations for Diagnosis and Management of Helicobacter pylori-Synthesizing the Guidelines.

Authors:  David J Bjorkman; Matthew Steenblik
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

3.  Molecular Detection of Antibiotic-Resistant Helicobacter pylori.

Authors:  Denise Brennan; Colm O'Morain; Deirdre McNamara; Sinéad M Smith
Journal:  Methods Mol Biol       Date:  2021

Review 4.  First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines.

Authors:  Vincenzo De Francesco; Annamaria Bellesia; Lorenzo Ridola; Raffaele Manta; Angelo Zullo
Journal:  Ann Gastroenterol       Date:  2017-06-01

5.  Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis.

Authors:  Xiaoguang Shi; Junhong Zhang; Lingshan Mo; Jialing Shi; Mengbin Qin; Xue Huang
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

6.  Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance.

Authors:  Angel Cosme; Milagrosa Montes; Begoña Ibarra; Esther Tamayo; Horacio Alonso; Usua Mendarte; Jacobo Lizasoan; Marta Herreros-Villanueva; Luis Bujanda
Journal:  World J Gastroenterol       Date:  2017-05-14       Impact factor: 5.742

7.  The magnitude of antibiotic resistance to Helicobacter pylori in Africa and identified mutations which confer resistance to antibiotics: systematic review and meta-analysis.

Authors:  Hyasinta Jaka; Jee Ah Rhee; Linda Östlundh; Luke Smart; Robert Peck; Andreas Mueller; Christa Kasang; Stephen E Mshana
Journal:  BMC Infect Dis       Date:  2018-04-24       Impact factor: 3.090

8.  Helicobacter pylori best treatment approach: should a national consensus be the best consensus?

Authors:  Christos Liatsos; Sotirios D Georgopoulos
Journal:  Ann Gastroenterol       Date:  2017-08-02

Review 9.  Treatment of Helicobacter pylori infection in atrophic gastritis.

Authors:  Edith Lahner; Marilia Carabotti; Bruno Annibale
Journal:  World J Gastroenterol       Date:  2018-06-14       Impact factor: 5.742

10.  Which should be the first-line treatment for Helicobacter pylori in Colombia? A lesson from a recent study.

Authors:  Rinaldo Pellicano
Journal:  Biomedica       Date:  2019-12-01       Impact factor: 0.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.